Skip to content
Review

Early experience with single-axillary-incision endoscopic nipple-sparing mastectomy and immediate DIEP flap breast reconstruction.

Oct 2026 · Journal of Plastic, Reconstructive & Aesthetic Surgery · Vol 124, pp. 81-91 · 0 citations · 28 references
Medicine

Abstract

Background

Endoscopic nipple-sparing mastectomy (ENSM) has been increasingly adopted to improve cosmetic outcomes while maintaining oncologic safety. However, most ENSM reconstructions continue to be implant-based, and data on autologous reconstruction-particularly on deep inferior epigastric artery perforator (DIEP) flaps-are limited. Here, we evaluated the feasibility and outcomes of single-axillary-incision ENSM (SAI-ENSM) combined with immediate DIEP flap reconstruction.

Methods

A retrospective review was conducted by including consecutive patients undergoing SAI-ENSM with immediate DIEP flap reconstruction between December 2022 and December 2025. Demographic, oncologic, and surgical variables, and postoperative complications, were analyzed. Patient-reported outcomes (PRO) were assessed using a postoperative questionnaire.

Results

Twenty patients underwent unilateral reconstruction. The mean total operative time was 474.0 ± 81.2 min and mean final incision length was 7.3 ± 1.4 cm. No cases required conversion to nipple-areolar complex (NAC) resection, and all surgical margins were negative. Postoperative complications, including total skin necrosis (5%) and total NAC necrosis (5%), occurred in 30% of the patients; no reoperations or total flap loss occurred. PRO demonstrated high satisfaction in terms of scar appearance (88.2%), scar location (100%), and breast appearance (76.5-88.2%).

Conclusions

SAI-ENSM combined with immediate DIEP flap reconstruction is a feasible and safe approach that yields inconspicuous scars, favorable esthetic outcomes, and high patient satisfaction. This approach offers a cost-effective alternative to robotic techniques without the need for specialized equipment, supporting its potential for broader clinical adoption. Further studies with longer follow-up are warranted to confirm oncologic safety and long-term outcomes.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.